Tonix Pharmaceuticals (TNXP) shares soared in premarket trading after the company said the US Food and Drug Administration has accepted its filing of a new drug application for TNX-102 SL to treat fibromyalgia.
The biopharmaceutical company said the FDA is expected to assign the application a target action date within 74 days from the date of its NDA submission.
Tonix said its application is supported by data from two phase 3 clinical trials evaluating the safety and efficacy of TNX-102 SL as a bedtime treatment for fibromyalgia.
Tonix shares were 177% higher in recent premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments